DS 5141bAlternative Names: DS5141b
Latest Information Update: 12 Feb 2016
At a glance
- Originator Daiichi Sankyo Inc
- Mechanism of Action Dystrophin expression stimulants; Protein synthesis modulators; RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 01 Oct 2015 Phase-I/II clinical trials in Duchenne muscular dystrophy in Japan (SC) (NCT02667483)